Study Protocol of a Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in COVID-19 Patients with Comorbidities
Journal
Advances in therapy
Date Issued
2024
Author(s)
Abstract
Ropeginterferon alfa-2b represents a new-generation PEGylated interferon. It is approved for the treatment of polycythemia vera and shows promising anti-SARS-CoV-2 activities.
Subjects
Anti-SARS-CoV-2 drugs; Anti-SARS-CoV-2 efficacy; COVID-19; Patients with comorbidities; Randomized clinical trial; Ropeginterferon alfa-2b
Type
journal article